Axsome Therapeutics (AXSM) Cash & Equivalents (2015 - 2026)

Axsome Therapeutics has reported Cash & Equivalents for 12 years, with the latest figure at $305.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 1.4% year-over-year to $305.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305.1 million (up 1.4% YoY) and the FY2025 annual result came in at $322.9 million, up 2.4% from the prior year.
• Cash & Equivalents declined to $305.1 million in Q1 2026 per AXSM's latest filing, from $322.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $437.1 million in Q2 2023 and troughed at $73.4 million in Q2 2022.
• A 5-year average of $289.4 million and a median of $315.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 48.57% in 2022, then soared 495.57% in 2023.
• Over 5 years, Cash & Equivalents stood at $200.8 million in 2022, then soared by 92.29% to $386.2 million in 2023, then decreased by 18.34% to $315.4 million in 2024, then advanced by 2.4% to $322.9 million in 2025, then declined by 5.52% to $305.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $305.1 million, $322.9 million, and $325.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.